Wedbush analyst David Nierengarten downgrades Applied Genetic Techs (NASDAQ:AGTC) from Outperform to Neutral.
Canaccord Genuity Maintains Buy on Evolent Health, Lowers Price Target to $48
Canaccord Genuity analyst Richard Close maintains Evolent Health (NYSE:EVH) with a Buy and lowers the price target from $55 to $48.